Introduction
The term 'frail older people' has been defined as people over 75 years of age with geriatric syndrome, i.e. the presence of numerous chronic diseases and signs and symptoms such as incontinence, falls, cognitive impairment and reduced mobility (Saavreda Muñoz and Barreto Mar tín, 2008) . However, some older people are 'frail' before the age of 75 years. Therefore, frailty in older people should generally be associated with older people who have advanced, progressive, incurable illness and/or considerable health and social needs (Depar tment of Health, 2001 ).
The process of dying in frail older people requiring 24-hour care appears to differ from, for example, the process of dying in mid-life from cancer (Hockley and Clark, 2002) . People dying with a cancer diagnosis generally maintain high functional capacity up until the final 3 months of life, when there is a marked decline (Lunney et al, 2003; Costantini et al, 2008) . However, frail older people tend to follow a dwindling trajectory towards death in that they gradually become more disabled (Lynn and Adamson, 2003) . Their functional deterioration par ticularly worsens in their final year of life, when they can become much more dependent in terms of activities of living (Lunney et al, 2003; Costantini et al, 2008) . Death in frail older people can also be relatively unexpected, e.g. frail older people can die 'suddenly' from silent pneumonia or quietly in their sleep (Lynn and Adamson, 2003) .
Frail older people often have multiple morbidities, which may be complicated by varying degrees of dementia/cognitive impairment (Rashidi et al, 2011) . For example, Lievesley et al (2011) under took a survey of all residents living in Bupa's UK care homes in 2009. The most commonly occurring disorders were dementia (43.6%), stroke (20.2%), hear t disease (20.6%) and ar thritis (18.3%). Although these data are only from one care home provider, they provide an indication that the end-of-life needs of people dying in care homes may differ from individuals dying of cancer. Therefore, when considering the management of frail older people in care homes, it is important that health professionals with a background in caring for people with advanced cancer do not impose their previous knowledge of symptom control on the frail elderly population without appropriate translation.
Symptom control for people dying from advanced cancer can be complex and requires the use of several medications, including morphine, which are often delivered by a syringe driver in the last days of life (Twycross and Wilcock, 2011) . Many frail older people also have symptoms that require assessment and management if they are to be cared for in a dignified and compassionate manner, especially as they come to the end of their lives. However, whilst symptom presence and severity in this population are often caused by multiple factors, which interact, rather than a single aspect, frail older people often require significantly less parenteral medication than younger people (Rashidi et al, 2011) . (Parenteral medication is the term that describes the introduction of a medication into the body via a route other than the mouth, e.g. via an infusion or injection.) Kinley and Hockley (2010) under took a baseline review of 48 nursing home residents' medication in their last month of life and found that, out of the 11 residents who had a syringe driver in the last days of life, eight of the syringe drivers were in place for less than 1.5 days. That indicates that in the last days of life, symptom control needs of older people may be more appropriately managed through the use of bolus subcutaneous medication or rectal suppositories (Kinley and Hockley, Julie Kinley, Louisa Stone, Jo Hockley 2010). Also, a concern repor ted in this baseline review was that as syringe drivers are rarely used in nursing homes, nurses working in these settings lack competence in setting up a syringe driver.
The process of dying in the frail older population is not thought to be painful (Worcester, 1940) . In the authors' experience, many frail older people in care homes have died without needing an opiate and indeed often required no medication at all. If a person has had codeine/ paracetamol for symptom control such as ar thritic pain, then often an equivalent transdermal patch is all that is necessary. However, it is still good practice for all care homes to ensure that parenteral medication is available in anticipation of residents developing symptoms in the last days of life. Anticipatory medications are generally administered when the resident can no longer swallow (Amass and Allen, 2005 The guideline does not address every symptom that may be experienced by frail older people who are dying in care homes and does not intend to replace national and local palliative care guidelines that are currently in use. Specifically, the aim of the guideline is to highlight best practice with regard to the pharmaceutical management of three common symptoms that may affect frail older people in their last days of life -terminal restlessness, pain and excessive secretions (Hockley et al, 2004) . It is anticipated that it will be of relevance to GPs, care home managers and nurses, district nurses and community specialist palliative care teams with a remit for care homes.
It is recommended that the guideline be used in practice alongside an end-of-life guidance tool, such as the integrated care plan for the last days of life for residents in care homes (an adapted version of the LCP) (Hockley et al, 2004) , the Gold Standards Framework in Care Homes minimum care protocol (Badger et al, 2007; Gold Standards Framework, 2009) 
Literature search strategy
The following electronic databases were searched on 20 December, 2012, for ar ticles repor ting on the use of anticipatory medication in the last days of life for older/ frail people: Medline, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase and the Cochrane Library. The search was limited by language (English language) but not by date. The search strategy used free-text words and relevant subject headings to expose the chosen topic: 'older people', 'elderly', 'aging', 'last days of life', 'end of life', 'dying', 'terminal care', 'terminally ill', 'palliative care', 'palliative therapy', 'drugs', 'medications', 'pharmacological', 'anticipatory medication', 'crisis medication', 'pharmacokinetics', 'pharmacological', 'pharmaceutical', 'nursing homes', 'long term care', 'long term facilities', 'homes for the aged', 'health services for the aged', 'residential care', 'elderly care'. Selected ar ticles were examined and relevant citations obtained. The inclusion criteria were: empirical papers, including systematic reviews; exper t opinions and clinical guidelines; palliative care drug formularies; papers relating specifically to the pharmaceutical management of terminal restlessness, pain and excessive secretions at the end of life in frail older patient populations (aged 65+ years). Studies not specifically repor ting on anticipatory end-of-life medication for the symptom control of terminal restlessness, pain or excessive secretions in frail older people were excluded. In addition, reference books (i.e. Oxford Textbook of Palliative Nursing, Dementia: From Advanced Disease to Bereavement and the Palliative Care Formulary) were examined for information on the specific medications highlighted within the literature searched. Whilst this was not a systematic literature review and the data were not ranked, the search did reveal that there is little evidence on this topic. That which was found was predominantly exper t opinion.
Evidence
The guideline addresses the management of terminal restlessness, pain and excessive secretions in the last days of life, specific to frail older people. Where there was no evidence for this population, the evidence was taken from the cancer literature with caution. The recommendation for frail older people is to 'star t low and go slow' (Travis et al, 2001 ). 
i) Terminal restlessness

Treatment
The analgesic and its dose will depend upon the resident's previous analgesic use and clinical problems, e.g. many residents will have renal impairment. Physiological changes in the older person may mean that drugs can have a longer duration of action than would normally be expected (Chau et al, 2008) . In opioid-naïve residents the lowest opioid dose is recommended ( Table  2) . It must also be remembered that Table 1 Anticipatory medication for terminal restlessness and supporting evidence Table 2 Anticipatory medication for pain and supporting evidence Note that patches have slow onset of action and can take 12-24 hours after initial application before a steady state is reached (Pace et al, 2011; Watson et al, 2011; Prommer and Fieck, 2012) pain may not be solely physical, but can have emotional, spiritual and social aspects, which should always be addressed where possible (Kumar and Allcock, 2008) .
With regard to dose-equivalents for strong opioids (British National Formulary, 2013) , readers should refer to the European Association for Palliative Care (EAPC) evidencebased recommendations (Caraceni et al, 2012) , and palliative care medicine information (Twycross and Wilcock, 2011; British National Formulary, 2013) . It should be noted that differences of opinion regarding doses remain within the literature. However, dose ratios should be regarded as estimates and be used as guides. In prescribing for frail older people, where there is a range, the lowest dose should be used. The individual patient's medical condition must be taken into consideration every time there is a drug or dose change. The dose equivalents for morphine that St Christopher's Hospice uses in clinical practice are detailed at the end of the guideline.
iii) Secretions
Presentation Where secretions have gathered in the upper airways and oropharynx, noisy, moist, 'bubbly' breathing is heard (Pace et al, 2011; Watson et al, 2011) . This condition is not thought to be distressing for the patient but can be unsettling for relatives (Watson et al, 2011) . Excessive secretions usually occur when dying patients are unconscious or too weak to expectorate and are considered a clinical indicator that death may soon occur, i.e. hours or days (Wee and Hillier, 2009).
Treatment
Treatment needs to commence early, i.e. as soon as there is any sign that secretions are occurring. It is easier to stop secretions from forming than to remove those that have developed. There are two possible options and choice should be based on clinical condition (Table 3) .
Table 3
Anticipatory medication for secretions and supporting evidence Suction is not usually effective and can be distressing for the person (Pace et al, 2011) . Whilst a dry mouth is common at the end of life, the use of anticholinergic medications can potentiate dry mouth and therefore regular mouth care must always be carried out (Pace et al, 2011) . Some residents may still continue to have 'bubbly' breathing, despite optimal use of anticholinergic medication. Repositioning can be effective in some cases, e.g. positioning the patient in a semi-prone position to encourage drainage or, if the secretions are the result of pulmonary oedema or gastric reflux, positioning in an upright or semirecumbent position (Wee and Hillier, 2009; Twycross and Wilcock, 2011) .
Residents' relatives/loved ones need to be reassured that the secretions are not thought to distress the dying person (Wee et al, 2006a,b; Pace et al, 2011) .
Other symptoms
Although not the remit of this set of guidelines, other less common symptoms for frail older people at the end of life include nausea and vomiting and breathlessness. St Christopher's Hospice best-practice advice with regard to anticipatory prescribing for these symptoms is as follows: 
Conclusion
Medications for terminal restlessness, pain and excessive secretions need to be anticipated and appropriately prescribed to ensure distress in the last days of life is prevented and a dignified death achieved. Specialist palliative care has developed guidance for the control of symptoms at the end of life for people dying from cancer. However, palliative care principles relating to people dying from cancer need to be modified for people dying from non-malignant disease and, in par ticular, frail older people dying from multiple morbidities.
A detailed copy of our medication guidance can be found at: http://www.stchristophers. org.uk/sites/default/files/education/steps_ stepthree_guidance_drug_sheet.pdf
The guideline was developed in association with nurse managers from participating care homes, a local Macmillan GP advisor, and the pharmacist and medical team at St Christopher's Hospice, London. It was updated in January 2013 and review is planned for January 2015.
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